Exact Sciences (EXAS) Tops Q2 EPS by 12c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Exact Sciences Announces Second Quarter 2025 Results
August 6, 2025 4:05 PM EDTReports record revenue, improves adjusted EBITDA, raises full-year guidance
Second quarter and recent highlights
Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests Gained Medicare coverage for Oncodetect molecular residual disease and recurrence monitoring test Announced a multi-year... More